What are the precautions for Pitobrutinib?

Pitobrutinib, an important kinase inhibitor, is widely used to treat certain types of lymphoma. However, like other medications, its use may come with a range of potential side effects and risks that require close attention and management by patients and healthcare teams.

Infection risk: Patients are at risk for serious and fatal infections caused by bacteria, viruses, or fungi after using pitobrutinib. According to statistics, about24% of infection incidents are grade 3 or higher. In addition, there is the possibility of opportunistic infections, such as Pneumocystis jiroveci pneumonia. For those at high risk, preventive measures, such as vaccinations and antibiotics, should be taken to reduce the risk of infection.

Bleeding Events: Serious and fatal bleeding events have been reported with the use of pitobrutinib. Therefore, patients should closely monitor any signs of bleeding, such as bruising, nosebleeds, bleeding gums, etc., and report them immediately to the medical team for appropriate management.

Decreased blood cell counts: During treatment, patients may experience lower than normal blood cell counts, including neutrophils, platelets, or red blood cells. Healthcare providers will monitor patients' blood counts regularly throughout treatment and make appropriate adjustments and treatments as needed.

Risk of cardiac arrhythmias: Use of pitobrutinib may increase the risk of cardiac arrhythmias, including atrial fibrillation and atrial flutter. Patients should receive regular electrocardiograms so that any potential heart rhythm problems can be identified and treated promptly.

Fetal Harm: Pitobrutinib may cause fetal harm. Therefore, women of childbearing age should take effective contraceptive measures and avoid pregnancy during treatment. At this time, the safety and effectiveness of this drug in children are unknown, and its use in children is not recommended.

In addition to the above risks, patients should also use sun protection to reduce the risk of skin cancer. Overall, although pitobrutinib provides a new treatment option for lymphoma patients, its potential side effects and risks should be closely monitored and managed during use.

xa0

Reference: https://www.drugs.com/pirtobrutinib.html